DK0560136T3 - Neurobeskyttende lægemiddel - Google Patents

Neurobeskyttende lægemiddel

Info

Publication number: DK0560136T3
Authority: DK; Denmark
Prior art keywords: cerebral; neuroprotective drug; neuroprotecting; distrubance; pyrrol
Prior art date: 1992-02-25

Application number

DK93102957.3T

Other languages

English (en)

Inventor

Noriko Yamamoto

Koichi Yokota

Akira Yamashita

Keizo Ito

Original Assignee

Kanebo Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-02-25

Filing date

1993-02-25

Publication date

1996-02-26

1993-02-25 Application filed by Kanebo Ltd filed Critical Kanebo Ltd

1996-02-26 Application granted granted Critical

1996-02-26 Publication of DK0560136T3 publication Critical patent/DK0560136T3/da

Links

239000003814 drug Substances 0.000 title abstract 2
229940079593 drug Drugs 0.000 title abstract 2
230000000324 neuroprotective effect Effects 0.000 title 1
206010008111 Cerebral haemorrhage Diseases 0.000 abstract 1
206010021143 Hypoxia Diseases 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
230000005978 brain dysfunction Effects 0.000 abstract 1
230000002490 cerebral effect Effects 0.000 abstract 1
206010008118 cerebral infarction Diseases 0.000 abstract 1
208000026106 cerebrovascular disease Diseases 0.000 abstract 1
-1 ethyl 2-[4,5-bis(4-methoxyphenyl)thiazol-2-yl]pyrrol-1-yl Chemical group 0.000 abstract 1
230000007954 hypoxia Effects 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Hospice & Palliative Care (AREA)
Organic Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

DK93102957.3T 1992-02-25 1993-02-25 Neurobeskyttende lægemiddel DK0560136T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP4075256A JPH05229943A (ja)	1992-02-25	1992-02-25	脳保護剤

Publications (1)

Publication Number	Publication Date
DK0560136T3 true DK0560136T3 (da)	1996-02-26

Family

ID=13570960

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK93102957.3T DK0560136T3 (da)	1992-02-25	1993-02-25	Neurobeskyttende lægemiddel

Country Status (9)

Country	Link
US (1)	US5399571A (da)
EP (1)	EP0560136B1 (da)
JP (1)	JPH05229943A (da)
KR (1)	KR100247845B1 (da)
AT (1)	ATE133335T1 (da)
DE (1)	DE69301360T2 (da)
DK (1)	DK0560136T3 (da)
ES (1)	ES2085665T3 (da)
GR (1)	GR3018787T3 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2434493T3 (es)	2002-03-14	2013-12-16	Takeda Pharmaceutical Company Limited	Regulador del VDAC
JP4484439B2 (ja) *	2002-03-14	2010-06-16	国立大学法人東京工業大学	Ｖｄａｃ調節剤
US10471207B2 (en)	2008-12-29	2019-11-12	Medtronic Minimed, Inc.	System and/or method for glucose sensor calibration
US9289168B2 (en) *	2008-12-29	2016-03-22	Medtronic Minimed, Inc.	System and/or method for glucose sensor calibration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4168315A (en) *	1977-09-28	1979-09-18	The Upjohn Company	Dianisyl thiazole compound, compositions and method of antithrombotic treatment
US4659726A (en) *	1984-04-19	1987-04-21	Kanebo, Ltd.	Novel 4,5-Bis (4-methoxyphenyl)-2-(pyrrol-2-yl) thiazoles and pharmaceutical composition containing the same

1992
- 1992-02-25 JP JP4075256A patent/JPH05229943A/ja active Pending
1993
- 1993-02-12 US US08/016,860 patent/US5399571A/en not_active Expired - Fee Related
- 1993-02-24 KR KR1019930002589A patent/KR100247845B1/ko not_active Expired - Fee Related
- 1993-02-25 EP EP93102957A patent/EP0560136B1/en not_active Expired - Lifetime
- 1993-02-25 ES ES93102957T patent/ES2085665T3/es not_active Expired - Lifetime
- 1993-02-25 DE DE69301360T patent/DE69301360T2/de not_active Expired - Fee Related
- 1993-02-25 AT AT93102957T patent/ATE133335T1/de not_active IP Right Cessation
- 1993-02-25 DK DK93102957.3T patent/DK0560136T3/da active
1996
- 1996-01-25 GR GR950403720T patent/GR3018787T3/el unknown

Also Published As

Publication number	Publication date
ATE133335T1 (de)	1996-02-15
DE69301360T2 (de)	1996-07-11
DE69301360D1 (de)	1996-03-07
JPH05229943A (ja)	1993-09-07
EP0560136A1 (en)	1993-09-15
EP0560136B1 (en)	1996-01-24
US5399571A (en)	1995-03-21
ES2085665T3 (es)	1996-06-01
KR930017579A (ko)	1993-09-20
GR3018787T3 (en)	1996-04-30
KR100247845B1 (ko)	2000-04-01

Similar Documents

Publication	Publication Date	Title
FI933946A7 (fi)	1994-03-11	Hypoglykeemisinä aineina ja Alzheimerin taudin hoidossa käyttökelpoisia yhdisteitä
FI935306A7 (fi)	1994-06-17	Puhdistettujen, pintaa modifioivien aineiden käyttö estämään hiukkasten kasautumista steriloinnin aikana
FI954718A0 (fi)	1995-10-04	Heterosykliset johdannaiset iskeemian ja vastaavien sairauksien hoitamiseksi
NO990542D0 (no)	1999-02-05	K-252a-derivater og anvendelse av K-252a-derivater
FI950467L (fi)	1995-03-31	Terfenadiinin metaboliitit ja niiden optisesti puhtaat isomeerit allergisten sairauksien hoitamiseksi
AU3951389A (en)	1990-03-29	The use of alpha-amino boronicacid derivatives for the prophylaxis and treatment of virus diseases
NO302523B1 (no)	1998-03-16	Heterosykliske forbindelser, farmasöytiske preparater som omfatter dem, og anvendelse av forbindelsene for fremstilling av medikamenter
FI933902A7 (fi)	1994-03-10	Substituoidut sykloheksaanijohdannaiset sairauksien hoitamiseksi
NO943521L (no)	1995-03-27	Anvendelse av et pyrrolidinacetamidderivat for fremstilling av et terapeutikum
FI951511A7 (fi)	1995-03-30	IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaesto on tai hoitoon
AU2806692A (en)	1993-05-03	Medicament for the treatment of anxiety
DK0560136T3 (da)	1996-02-26	Neurobeskyttende lægemiddel
IT1271567B (it)	1997-05-30	Procedimento per l'ulteriore trattamento di salcicce
ATE183088T1 (de)	1999-08-15	Arzneimittel zur behandlung von hauterkrankungen
NO923198D0 (no)	1992-08-14	Terapeutiske midler
NO970185D0 (no)	1997-01-15	Anvendelse av (S)-adenosyl-L-metionin (SAMe) og dets fysiologisk kompatible salter for behandling av reperfusjonsskade utlöst av temporær-fokal-ischemi
NO960545D0 (no)	1996-02-12	Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin
EP0454429A3 (en)	1992-07-15	Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
DE68901172D1 (de)	1992-05-14	(-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
ITMI920161A1 (it)	1993-07-29	Medicamento contenente arg-gly-asp per il trattamento del glaucoma
FR2691064B3 (fr)	1996-01-12	Nouveau medicament pour le traitement de l'arythmie.
BR9205712A (pt)	1994-06-07	Medicamento e processo para a preparaçao de um medicamento
SE8703308D0 (sv)	1987-08-26	Therapeutic agent for the treatment of disorders associated with cerebral ischemia
HU908017D0 (en)	1991-06-28	Process for the preparation of naphloxazines and medical preparation made of them
ES2039255T3 (es)	1993-09-16	Utilizacion de n-((1-etil-2-pirrolidinil)metil)-2-metoxi-5-sulfamoil-benzamida en el tratamiento de la esterilidad.